Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Galapagos has signed a drug discovery research agreement with University College London. Total contract value for Galapagos is expected to reach more than E1.8 million over the course of the two-year agreement.
Subscribe to our email newsletter
UCL (University College London) has an ongoing drug discovery program for the treatment of vascular collapse during sepsis (collapsing of blood vessels due to systemic infection by a pathogen). Galapagos’s BioFocus DPI service division will provide medicinal chemistry services to progress UCL’s lead series through to pre-clinical testing.
In addition UCL will also have the opportunity to utilize BioFocus DPI ADME screening services and will receive access to a selection of compounds in BioFocus DPI’s SoftFocus collection to facilitate the identification of new chemical starting points for this drug discovery program.
Onno van de Stolpe, CEO of Galapagos, said: “BioFocus DPI’s medicinal chemistry and ADME expertise, such as the newly launched ADME/PK Laboratory, give us a strong edge in winning highly competitive deals.”